Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/26471
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2030-01-01
Colecciones
- IOC - Artigos de Periódicos [12502]
Metadatos
Mostrar el registro completo del ítem
ORAL DELIVERY OF BCG MOREAU RIO DE JANEIRO GIVES EQUIVALENT PROTECTION AGAINST TUBERCULOSIS BUT WITH REDUCED PATHOLOGY COMPARED TO PARENTERAL BCG DANISH VACCINATION
Vacina BCG Moreau Rio de Janeiro
Administração oral
Tuberculose
Autor
Afiliación
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil / Fundação Ataulpho de Paiva. Ri de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia em Tuberculose. Rio de Janeiro, RJ, Brasil.
University of Otago. Centre for Innovation. Dunedin, New Zealand.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
St George’s University of London. St George’s Vaccine Institute. London, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil / Fundação Ataulpho de Paiva. Ri de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia em Tuberculose. Rio de Janeiro, RJ, Brasil.
University of Otago. Centre for Innovation. Dunedin, New Zealand.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
St George’s University of London. St George’s Vaccine Institute. London, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Resumen en ingles
There is a need for an improved vaccine to better control human tuberculosis (TB), as the only currently available TB vaccine, bacillus Calmette-Guerin (BCG) delivered parenterally, offers variable levels of efficacy. Therefore, recombinant strains expressing additional antigens are being developed alongside alternative routes to parenteral delivery. There is strong evidence that BCG Moreau (RdJ) is a safe and effective vaccine in humans when given by the oral route. This study compared the efficacy of a single oral dose of wild type BCG Moreau Rio de Janeiro (RdJ), or a recombinant RdJ strain expressing Ag85B-ESAT6 fusion protein, formulated with and without lipid to enhance oral delivery, with subcutaneous BCG Danish 1331 and saline control groups in a guinea pig aerosol infection model of pulmonary tuberculosis. Protection was measured as survival at 30 weeks post-challenge and reduced bacterial load and histopathology in lungs and spleen. Results showed that a single oral dose of BCG Moreau (RdJ) or recombinant BCG Moreau (RdJ)-Ag85B-ESAT6, formulated with or without lipid, gave protection equivalent to subcutaneously delivered BCG Danish in the 30 weeks post-challenge survival study. The orally delivered vaccines gave reduced pathology scores in the lungs (three of the four formulations) and spleens (all four formulations) compared to subcutaneously delivered BCG Danish. The oral wild type BCG Moreau (RdJ) in lipid and the unformulated oral wild type BCG Moreau (RdJ) vaccine also gave statistically lower bacterial loads in the lungs and spleens, respectively, compared to subcutaneously delivered BCG Danish. This study provides further evidence to show that lipid formulation does not impair vaccine efficacy and may enhance the delivery and stability of oral vaccines intended for use in countries with poor health infrastructure. Oral delivery also avoids needles (and associated cross-infection risks) and immunisation without the need for specially trained medical professional staff.
Palabras clave en portugues
Mycobacterium bovisVacina BCG Moreau Rio de Janeiro
Administração oral
Tuberculose
Compartir